CHARACTERISTICS OF TOXIN-NEUTRALIZATION BY ANTITETANUS HUMAN MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE 3 FUNCTIONAL DOMAINS [A], [B] AND [C] OF THE TETANUS TOXIN MOLECULE AND A RELIABLE METHOD FOR EVALUATING THE PROTECTIVE EFFECTS OF MONOCLONAL-ANTIBODIES

被引：26

作者：

MATSUDA, M

KAMEI, M

SUGIMOTO, N

MA, Y

HASHIZUME, S

机构：

[1] Department of Tuberculosis Research-Research Institute for Microbial Diseases, Osaka University, Suita-Osaka, 565

[2] Morinaga Institute of Biological Science, Yokohama Kanagawa, 230

来源：

EUROPEAN JOURNAL OF EPIDEMIOLOGY | 1992年 / 8卷 / 01期

关键词：

TOXIN-NEUTRALIZATION; ANTITETANUS MONOCLONAL ANTIBODIES; HUMAN MONOCLONAL ANTIBODIES; PROTECTION AGAINST TETANUS;

D O I：

10.1007/BF02427384

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Five anti-tetanus human monoclonal antibodies (MAbs) produced by hybrid cell lines we established previously were characterized. Their abilities to neutralize tetanus toxin in vitro and to protect mice against challenge with toxin were studied by observing the changes in the progress of symptoms in mice. Immunostaining showed that MAbs MAb-G4 and G2 recognized the N-terminal domain, [A] and the C-terminal domain, [C] of the tetanus toxin molecule, respectively, while MAbs MAb-G1, G3 and G6 recognized its middle domain, [B]. Enzyme-linked immunosorbent assay showed that the binding affinity of MAb-G3 was 2.9 X 10(10) M-1 and those of the other MAbs were as high as approximately 10(11) M-1. In in vitro neutralization experiments, at sufficient doses all the MAbs as single reagents protected mice completely against the effect of tetanus toxin. However, at lower doses than those sufficient to rescue mice, the kinetic patterns of progress of symptoms with the individual MAbs differed with each other and, except for MAb-G4, were different from that of anti-tetanus human polyclonal antibody. They suppressed the development and/or slowed the rate of progress of symptoms for over 96 h and delayed death of the mice. We propose that the comparison of the minimum survival dose with that of human polyclonal antibody of known international units is a reliable method for estimating the actual protective activity of a MAb. Intravenous (IV) injection of doses of individual MAbs or their mixtures at over 0.03 IU per mouse protected mice from subsequent challenge with 20 MLD of tetanus toxin. Moreover, mice could be rescued by IV injection of individual MAbs or their mixture at doses equivalent to 0.03 IU per mouse, even 10 h after intramuscular (IM) injection of 4 MLD of tetanus toxin. The importance of these findings for evaluating the protective effects of anti-tetanus MAbs for clinical use is discussed.

引用

页码：1 / 8

页数：8

共 29 条

[1]

Ahnert-Hilger G., Bizzini B., Goretzki K., Muller H., Volckers C., Habermann E., Monoclonal antibodies against tetanus toxin and toxoid, Med. Microbiol. Immunol., 172, pp. 123-135, (1983)

[2]

Chiorazzi N., Wasserman R.L., Kunkel H.G., Use of Epstein-Barr virus-transformed B cell lines for the generation of immunoglobulin-producing human B cell hybridomas, J. Exp. Med., 156, pp. 930-935, (1982)

[3]

Ebisawa I., Matsuhashi C., Yamamoto A., Kurosu Y., Otsuka T., Clinical experience in the use of intravenously injectable tetanus-immune human gamma globulin TIG(i), Kansenshogaku Zasshi (J. Jpn. Assoc. Infect. Dis.), 55, pp. 92-98, (1981)

[4]

Gigliotti F., Insel R.A., Protective human hybridoma antibody to tetanus toxin, J. Clin. Invest., 70, pp. 1306-1309, (1982)

[5]

Habermann E., Goretzki K., Monoclonal antibodies against tetanus toxin and tetanus toxoid, Monoclonal Antibodies against Bacteria, Vol. I., pp. 191-205, (1985)

[6]

Hirata Y., Sugawara I., Characterization of mouse-human hybridoma as a useful fusion partner for the establishment of mouse-human-human hybridoma secreting anti-tetanus toxoid human monoclonal antibody of IgM or IgG class, Microbiol. Immunol., 31, pp. 231-245, (1987)

[7]

Ho M.-K., Rand N., Murray J., Kato K., Rabin H., In vitro immunization of human lymphocytes. I. Production of human monoclonal antibodies against bombesin and tetanus toxoid, J. Immunol., 135, pp. 3831-3838, (1985)

[8]

Ichimori Y., Sasano K., Itoh H., Hitotsumachi S., Kimura Y., Kaneko K., Kida M., Tsukamoto K., Establisment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen, Biochem. Biophys. Res. Commun., 129, pp. 26-33, (1985)

[9]

Kamei M., Hashizume S., Sugimoto N., Ozutsumi K., Matsuda M., Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity, Eur. J. Epidemiol., 6, pp. 386-397, (1990)

[10]

Kimoto H., A method for estimating the affinity of monoclonal antibodies — a solid phase method, Saibôkogaku (Cell Technology), 4, pp. 792-796, (1985)

← 1 2 3 →